Kenneth Maiese

List of Publications by Year
in descending order

135 papers	15,842 citations	18465 62 h-index	19169 118 g-index
135 all docs	135 docs citations	135 times ranked	21663 citing authors

#	Article	IF	Citations
1	Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1. Neural Regeneration Research, 2021, 16, 448.	1.6	50
2	Sirtuins in metabolic disease: innovative therapeutic strategies with SIRT1, AMPK, mTOR, and nicotinamide. , 2021, , 3-23.		4
3	Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes. Current Neurovascular Research, 2021, 17, 765-783.	0.4	8
4	Cognitive Impairment and Dementia: Gaining Insight through Circadian Clock Gene Pathways. Biomolecules, 2021, 11, 1002.	1.8	24
5	Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders. Current Neurovascular Research, 2021, 18, 134-149.	0.4	6
6	Novel treatment strategies for neurodegenerative disease with sirtuins. , 2021, , 3-21.		1
7	Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm. Frontiers in Bioscience, 2021, 26, 614.	0.8	16
8	Healing the Heart with Sirtuins and Mammalian Forkhead Transcription Factors. Current Neurovascular Research, 2020, 17, 1-2.	0.4	9
9	Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways. Expert Review of Clinical Pharmacology, 2020, 13, 23-34.	1.3	31
10	Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease. International Review of Neurobiology, 2020, 155, 1-35.	0.9	20
11	Prospects and Perspectives for WISP1 (CCN4) in Diabetes Mellitus. Current Neurovascular Research, 2020, 17, 327-331.	0.4	21
12	New Challenges and Strategies for Cardiac Disease: Autophagy, mTOR, and AMP-activated Protein Kinase. Current Neurovascular Research, 2020, 17, 111-112.	0.4	2
13	Heightened Attention for Wnt Signaling in Diabetes Mellitus. Current Neurovascular Research, 2020, 17, 215-217.	0.4	7
14	The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment. Current Neurovascular Research, 2020, 17, 332-337.	0.4	57
15	New Insights for nicotinamide Metabolic disease autophagy and mTOR. Frontiers in Bioscience - Landmark, 2020, 25, 1925-1973.	3.0	28
16	Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimerâ€™s Disease. Current Neurovascular Research, 2019, 15, 367-371.	0.4	22
17	The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders. Biochemical Society Transactions, 2018, 46, 351-360.	1.6	41
18	Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss. Current Neurovascular Research, 2018, 14, 415-420.	0.4	37

#	Article	IF	Citations
19	Novel Pathways of Autophagy for the Treatment of Nervous System Disorders. , 2018, , 187-197.		0
20	Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors. Current Neurovascular Research, 2018, 15, 81-91.	0.4	28
21	Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer. Current Neurovascular Research, 2017, 14, 299-304.	0.4	84
22	Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease. Current Neurovascular Research, 2017, 14, 82-88.	0.4	35
23	Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin. Current Neurovascular Research, 2017, 14, 184-189.	0.4	32
24	The bright side of reactive oxygen species: lifespan extension without cellular demise. Journal of Translational Science, 2016, 2, 185-187.	0.2	37
25	Regeneration in the nervous system with erythropoietin. Frontiers in Bioscience - Landmark, 2016, 21, 561-596.	3.0	48
26	Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. British Journal of Clinical Pharmacology, 2016, 82, 1245-1266.	1.1	160
27	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
28	Charting a course for erythropoietin in traumatic brain injury. Journal of Translational Science, 2016, 2, 140-144.	0.2	16
29	Forkhead transcription factors: new considerations for alzheimerâ€™s disease and dementia. Journal of Translational Science, 2016, 2, 241-247.	0.2	56
30	Disease onset and aging in the world of circular RNAs. Journal of Translational Science, 2016, 2, 327-329.	0.2	48
31	Erythropoietin and mTOR: A â€œOne-Two Punchâ€•for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. Current Neurovascular Research, 2016, 13, 329-340.	0.4	32
32	Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR. Neural Regeneration Research, 2016, 11, 372.	1.6	61
33	Novel Stem Cell Strategies with mTOR. , 2016, , 3-22.		5
34	Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease. Journal of Translational Science, 2016, 1, 83-85.	0.2	34
35	Paring Down Obesity and Metabolic Disease by Targeting Inflammation and Oxidative Stress. Current Neurovascular Research, 2015, 12, 107-108.	0.4	5
36	mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. World Journal of Diabetes, 2015, 6, 217.	1.3	51

#	Article	IF	Citations
37	FoxO Proteins in the Nervous System. Analytical Cellular Pathology, 2015, 2015, 1-15.	0.7	77
38	New Insights for Oxidative Stress and Diabetes Mellitus. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-17.	1.9	177
39	SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer. World Journal of Stem Cells, 2015, 7, 235.	1.3	63
40	Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regeneration Research, 2015, 10, 518.	1.6	75
41	Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus. Current Neurovascular Research, 2015, 12, 173-188.	0.4	42
42	FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus. Current Neurovascular Research, 2015, 12, 404-413.	0.4	72
43	Erythropoietin and diabetes mellitus. World Journal of Diabetes, 2015, 6, 1259.	1.3	47
44	Stem cell guidance through the mechanistic target of rapamycin. World Journal of Stem Cells, 2015, 7, 999-1009.	1.3	29
45	MicroRNAs and SIRT1: A Strategy for Stem Cell Renewal and Clinical Development?. Journal of Translational Science, 2015, 1, 55-57.	0.2	17
46	Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence. Current Neurovascular Research, 2014, 11, 1-3.	0.4	4
47	Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Annals of Medicine, 2014, 46, 587-596.	1.5	78
48	Cutting through the Complexities of mTOR for the Treatment of Stroke. Current Neurovascular Research, 2014, 11, 177-186.	0.4	59
49	WISP1: Clinical Insights for a Proliferative and Restorative Member of the CCN Family. Current Neurovascular Research, 2014, 11, 378-389.	0.4	83
50	Driving neural regeneration through the mammalian target of rapamycin. Neural Regeneration Research, 2014, 9, 1413.	1.6	77
51	mTOR: on target for novel therapeutic strategies in the nervous system. Trends in Molecular Medicine, 2013, 19, 51-60.	3.5	202
52	Novel directions for diabetes mellitus drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 35-48.	2.5	67
53	WISP1 Neuroprotection Requires FoxO3a Post-Translational Modulation with Autoregulatory Control of SIRT1. Current Neurovascular Research, 2013, 10, 54-69.	0.4	64
54	Tuberous Sclerosis Protein 2 (TSC2) Modulates CCN4 Cytoprotection During Apoptotic Amyloid Toxicity in Microglia. Current Neurovascular Research, 2013, 10, 29-38.	0.4	59

#	Article	IF	Citations
55	Therapeutic targets for cancer: current concepts with PI 3-K, Akt, & mTOR. Indian Journal of Medical Research, 2013, 137, 243-6.	0.4	14
56	Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade. International Journal of Molecular Sciences, 2012, 13, 13830-13866.	1.8	96
57	Erythropoietin: New Directions for the Nervous System. International Journal of Molecular Sciences, 2012, 13, 11102-11129.	1.8	78
58	A critical kinase cascade in neurological disorders: PI3K, Akt and mTOR. Future Neurology, 2012, 7, 733-748.	0.9	92
59	WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of Î²-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy. Current Neurovascular Research, 2012, 9, 91-101.	0.4	66
60	Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern β-Amyloid Apoptotic Injury of Microglia. Current Neurovascular Research, 2012, 9, 239-249.	0.4	68
61	Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovascular Diabetology, 2012, 11, 45.	2.7	94
62	Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiology, 2012, 8, 89-100.	0.5	102
63	Targeting disease through novel pathways of apoptosis and autophagy. Expert Opinion on Therapeutic Targets, 2012, 16, 1203-1214.	1.5	140
64	Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Progress in Neurobiology, 2012, 99, 128-148.	2.8	112
65	SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opinion on Therapeutic Targets, 2012, 16, 167-178.	1.5	148
66	PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection. PLoS ONE, 2012, 7, e45456.	1.1	77
67	Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Blocks Neurodegeneration through Phosphoinositide 3 Kinase/Akt1 and Apoptotic Mitochondrial Signaling Involving Bad, Bax, Bim, and Bcl-xL. Current Neurovascular Research, 2012, 9, 20-31.	0.4	67
68	Prevention of Î²-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging, 2012, 4, 187-201.	1.4	127
69	Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. Current Neurovascular Research, 2011, 8, 270-285.	0.4	96
70	EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes. Current Neurovascular Research, 2011, 8, 103-120.	0.4	91
71	Cardiovascular Disease and mTOR Signaling. Trends in Cardiovascular Medicine, 2011, 21, 151-155.	2.3	77
72	Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress. Current Neurovascular Research, 2011, 8, 220-235.	0.4	110

#	Article	IF	Citations
73	Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus. Journal of Clinical Pharmacology, 2011, 51, 128-152.	1.0	50
74	Early Apoptotic Vascular Signaling is Determined by Sirt1 Through Nuclear Shuttling, Forkhead Trafficking, Bad, and Mitochondrial Caspase Activation. Current Neurovascular Research, 2010, 7, 95-112.	0.4	107
75	Oxidative stress: Biomarkers and novel therapeutic pathways. Experimental Gerontology, 2010, 45, 217-234.	1.2	115
76	Wnt1, FoxO3a, and NF-Î°B oversee microglial integrity and activation during oxidant stress. Cellular Signalling, 2010, 22, 1317-1329.	1.7	92
77	Ringing in the New Year: New Prospects for Development, Aging and Longevity. Oxidative Medicine and Cellular Longevity, 2010, 3, 1-1.	1.9	8
78	Tolerance: A Virtue During Times of Stress. Oxidative Medicine and Cellular Longevity, 2010, 3, 167-167.	1.9	0
79	Metabolic Clues: Novel Directives for Broad Treatment Strategies. Oxidative Medicine and Cellular Longevity, 2010, 3, 289-289.	1.9	1
80	Yin Yang: A Balancing Act for Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2010, 3, 227-227.	1.9	3
81	Just in the Nick of Time: Targeting Acute versus Chronic Disease. Oxidative Medicine and Cellular Longevity, 2010, 3, 359-360.	1.9	0
82	Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders. Oxidative Medicine and Cellular Longevity, 2010, 3, 374-391.	1.9	146
83	Heal Thyself: Endogenous Pathways of Protection for Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2010, 3, 75-76.	1.9	2
84	Wnt1 Neuroprotection Translates into Improved Neurological Function during Oxidant Stress and Cerebral Ischemia ThroughAKT1and Mitochondrial Apoptotic Pathways. Oxidative Medicine and Cellular Longevity, 2010, 3, 153-165.	1.9	87
85	Diabetes Mellitus: Channeling Care through Cellular Discovery. Current Neurovascular Research, 2010, 7, 59-74.	0.4	37
86	FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Molecular and Cellular Endocrinology, 2010, 321, 194-206.	1.6	71
87	A Fork in the Path: Developing Therapeutic Inroads with FoxO Proteins. Oxidative Medicine and Cellular Longevity, 2009, 2, 119-129.	1.9	80
88	Environmental Stimulus Package: Potential for a Rising Oxidative Deficit. Oxidative Medicine and Cellular Longevity, 2009, 2, 179-180.	1.9	1
89	The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3. Current Neurovascular Research, 2009, 6, 20-31.	0.4	81
90	Erythropoietin, Forkhead Proteins, and Oxidative Injury: Biomarkers and Biology. Scientific World Journal, The, 2009, 9, 1072-1104.	0.8	47

#	Article	IF	Citations
91	New Strategies for Alzheimer Disease and Cognitive Impairment. Oxidative Medicine and Cellular Longevity, 2009, 2, 279-289.	1.9	62
92	A â€œFOXOâ€•in sight: Targeting Foxo proteins from conception to cancer. Medicinal Research Reviews, 2009, 29, 395-418.	5.0	116
93	The Vitamin Nicotinamide: Translating Nutrition into Clinical Care. Molecules, 2009, 14, 3446-3485.	1.7	212
94	FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clinical Science, 2009, 116, 191-203.	1.8	89
95	FoxO3a Governs Early Microglial Proliferation and Employs Mitochondrial Depolarization with Caspase 3, 8, and 9 Cleavage During Oxidant Induced Apoptosis. Current Neurovascular Research, 2009, 6, 223-238.	0.4	64
96	The â€œOâ€•Class: Crafting Clinical Care with FoxO Transcription Factors. Advances in Experimental Medicine and Biology, 2009, 665, 242-260.	0.8	61
97	The Wnt signaling pathway: Aging gracefully as a protectionist?. , 2008, 118, 58-81.		184
98	OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends in Molecular Medicine, 2008, 14, 219-227.	3.5	171
99	Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Progress in Neurobiology, 2008, 85, 194-213.	2.8	118
100	Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomedicine and Pharmacotherapy, 2008, 62, 218-232.	2.5	86
101	Raves and risks for erythropoietin. Cytokine and Growth Factor Reviews, 2008, 19, 145-155.	3.2	101
102	Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Review of Cardiovascular Therapy, 2008, 6, 281-284.	0.6	43
103	Clever cancer strategies with FoxO transcription factors. Cell Cycle, 2008, 7, 3829-3839.	1.3	63
104	Rogue proliferation versus restorative protection: Where do we draw the line for Wnt and Forkhead signaling?. Expert Opinion on Therapeutic Targets, 2008, 12, 905-916.	1.5	42
105	Life Span Extension and Neuronal Cell Protection by Drosophila Nicotinamidase. Journal of Biological Chemistry, 2008, 283, 27810-27819.	1.6	166
106	Erythropoietin and Oxidative Stress. Current Neurovascular Research, 2008, 5, 125-142.	0.4	118
107	Therapeutic Promise and Principles: Metabotropic Glutamate Receptors. Oxidative Medicine and Cellular Longevity, 2008, 1, 1-14.	1.9	35
108	Oxidative Stress Biology and Cell Injury During Type 1 and Type 2 Diabetes Mellitus. Current Neurovascular Research, 2007, 4, 63-71.	0.4	197

#	Article	IF	Citations
109	Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress. Current Medicinal Chemistry, 2007, 14, 1729-1738.	1.2	184
110	“SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain. Current Neurovascular Research, 2007, 4, 295-302.	0.4	86
111	Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling. Current Neurovascular Research, 2007, 4, 194-204.	0.4	100
112	Cellular demise and inflammatory microglial activation during Î2-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cellular Signalling, 2007, 19, 1150-1162.	1.7	113
113	Attempted Cell Cycle Induction in Post-Mitotic Neurons Occurs in Early and Late Apoptotic Programs Through Rb, E2F1, and Caspase 3. Current Neurovascular Research, 2006, 3, 25-39.	0.4	58
114	Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD+ Precursor Nicotinamide. Current Medicinal Chemistry, 2006, 13, 883-895.	1.2	127
115	Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress. Current Neurovascular Research, 2006, 3, 107-117.	0.4	88
116	Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors. Current Neurovascular Research, 2005, 2, 425-446.	0.4	63
117	Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Research Reviews, 2005, 49, 1-21.	9.1	161
118	Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Progress in Neurobiology, 2005, 75, 207-246.	2.8	519
119	New Avenues of Exploration for Erythropoietin. JAMA - Journal of the American Medical Association, 2005, 293, 90.	3.8	508
120	The NAD+ Precursor Nicotinamide Governs Neuronal Survival During Oxidative Stress Through Protein Kinase B Coupled to FOXO3a and Mitochondrial Membrane Potential. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 728-743.	2.4	154
121	AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Experimental Cell Research, 2004, 296, 196-207.	1.2	119
122	Erythropoietin in the brain: can the promise to protect be fulfilled?. Trends in Pharmacological Sciences, 2004, 25, 577-583.	4.0	186
123	Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restorative Neurology and Neuroscience, 2004, 22, 87-104.	0.4	70
124	Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. Journal of Neuroscience Research, 2003, 71, 659-669.	1.3	171
125	Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. British Journal of Pharmacology, 2003, 138, 1107-1118.	2.7	239
126	Apaf-1, Bcl-x_L, Cytochrome <i>c</i>, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 320-330.	2.4	174

#	Article	IF	Citations
127	Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends in Pharmacological Sciences, 2003, 24, 228-232.	4.0	193
128	Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases. Circulation, 2002, 106, 2973-2979.	1.6	401
129	Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. , 2000, 59, 568-580.		114
130	Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. Journal of Neuroscience Research, 2000, 62, 257-272.	1.3	89
131	Critical temporal modulation of neuronal programmed cell injury. Cellular and Molecular Neurobiology, 2000, 20, 383-400.	1.7	39
132	Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. , 1999, 40, 171-184.		70
133	Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. , 1999, 55, 472-485.		55
134	Neuroprotection of Lubeluzole Is Mediated Through the Signal Transduction Pathways of Nitric Oxide. Journal of Neurochemistry, 1997, 68, 710-714.	2.1	68
135	Cellular Mechanisms of Protection by Metabotropic Glutamate Receptors During Anoxia and Nitric Oxide Toxicity. Journal of Neurochemistry, 1996, 66, 2419-2428.	2.1	73